Ionis Pharmaceuticals’ Sapablursen was granted FDA orphan status as a treatment of polycythemia vera, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $51 from $45 at Barclays
- Ionis downgraded to Market Perform from Outperform at BMO Capital
- Ionis Pharmaceuticals says ‘on track to achieve 2024 financial guidance’
- Ionis Pharmaceuticals reports Q2 EPS (45c), consensus (92c)
- Ionis reports second quarter 2024 financial results